



Date: 12-02-2025

To  
The Corporate Relation Department  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400001

Dear Sir / Madam,

**Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018**

**Subject: Outcome of the Board Meeting held on Wednesday, 12th February 2025**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our intimation dated 07<sup>th</sup> February, 2025 regarding the Notice for the Board Meeting, the Board of Directors of the Company in their Meeting held today i.e., Wednesday, February 12, 2025, inter alia have considered and approved following important businesses:

1. Approved the Unaudited Standalone and Consolidated Financial Results along with the Limited Review Report for the quarter and nine months ended 31st December, 2024 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) which has been duly reviewed and recommended by the Audit Committee.

We are enclosing herewith the Unaudited Financial Results along with the Limited Review Report issued by M/s PPKG & Co, Statutory Auditors of the Company.

The Financial Results are also available on the website of the Company at [www.pharmaids.com](http://www.pharmaids.com) and on the website of BSE [www.bseindia.com](http://www.bseindia.com)

2. Re-appointment of Mr. Venu Madhava Kaparthy (DIN: 00021699) as Whole-time Director and designated as Executive Director, subject to the approval of the members of the Company.

Based on the recommendations of the Nomination and Remuneration Committee and subject to the approval of the Shareholders of the Company, the Board approved the re-appointment of Mr. Venu Madhava Kaparthy (DIN: 00021699), as Whole-time Director, not liable to retire by rotation, designated as Executive Director of the Company for a further period of 3 years with effect from May 21, 2025 including the payment of remuneration thereof;

The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are provided as **Annexure – A**

3. Re-appointment of Ms. Mini Manikantan (DIN: 09663184) as Whole-time Director and designated as Executive Director, subject to the approval of the members of the Company.

Based on the recommendations of the Nomination and Remuneration Committee and subject to the approval of the Shareholders of the Company, the Board approved the re-appointment of Ms. Mini Manikantan (DIN: 09663184), as Whole-time Director, liable to retire by rotation, designated as Executive Director of the Company for a further period of 3 years with effect from July 09, 2025 including the payment of remuneration thereof;

The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are provided as **Annexure – B**

4. Increase in Authorized Share Capital of the Company and alteration of Capital Clause of the Memorandum of Association of the Company, subject to the approval of shareholders of the Company.

The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are provided as **Annexure – C**

5. Considered and Approved the sale of Industrial land plots admeasuring approx. 3.45 acres owned by the Company situated at Manchakalkuppe Village, Urdagere Hobli, Tumkur Taluk, Tumkur District (“the land parcels”)

To align with the company’s strategy to explore and acquire land in more suitable locations for enhanced operational benefits the Board of Directors has approved the sale of the aforementioned land parcels for a total consideration of Rs. 16,50,00,000/- (Rupees Sixteen Crore Fifty Lakh Only) to Dr. S. N. Vinaya Babu, Chairman and Non-Executive & Non-Independent Director of the Company (“Buyer”) subject to the approval of the Shareholders of the Company.

Further the sale of the said land parcels constitute as an undertaking or substantially the whole of the undertaking for the Company in terms of section 180(1)(a) of the Companies Act, 2013 and Regulation 37A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are provided as **Annexure – D**



# Pharmaids Pharmaceuticals Limited

Any agreements, deeds, or related documents entered into by the company in this regard will be duly communicated to the stock exchange within the stipulated timeframe, in compliance with the disclosure requirements under Regulation 30 of the SEBI (LODR) Regulations, 2015.

6. Approved issuance of a corporate guarantee amounting upto Rs.25,00,00,000/- (Rupees Twenty Five Crore Only) to any Banks/Financial Institutions for securing term loan/working capital facilities to be availed by M/s Adita Bio Sys Private Limited (“Adita”), Material Subsidiary of the Company. The term loan/ working capital facilities will be utilised for purchase of plant & machinery and laboratory equipment’s along with working capital enhancements.

The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are provided as **Annexure – E**

7. Approved Notice to be sent to the shareholders for seeking approval for following items, through postal ballot by means of electronic voting (remote e-voting) (“Postal Ballot Notice”) in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities & Exchange Board of India:

<b>Resolution No.</b>	<b>Particulars</b>
1	Increase in Authorised Share Capital and consequent Alteration of Capital Clause of Memorandum of Association of the Company.
2	Approval for grant of Stock Options to the eligible employees of Subsidiary/Associate Company(ies) of the Company under Pharmaids Pharmaceuticals Limited Employee Stock Option Scheme - 2024
3	Approval for offer of shares to eligible employees of the Subsidiary/Associate Company(ies) of the Company under Pharmaids Pharmaceuticals Limited Employee Stock Purchase Scheme - 2024
4	Reappointment of Mr. Venu Madhava Kaparthy (DIN: 00021699) as a Whole time Director designated as an Executive Director.
5	Reappointment of Ms. Mini Manikantan (DIN: 09663184) as a Whole time Director designated as an Executive Director.
6	To approve Material Related Party Transaction limits with Anugraha Chemicals (“The firm”), subsidiary of the Company
7	To approve Material Related Party Transaction limits with Adita Bio Sys Private Limited (“Adita”), Material Subsidiary of the Company
8	To approve Material Related Party Transaction limits with Spring Labs (“The firm / Spring”), Step down Subsidiary of the Company



# Pharmaids Pharmaceuticals Limited

9	To approve Material Related Party Transaction with Dr. Shankarappa Nagaraja Vinaya Babu (Chairman and Non-Executive & Non-Independent Director of the Company), being related party of the Company.
10	To approve Material Related Party Transaction with Moki Financial Services, being related party of Pharmaids Pharmaceuticals Limited.
11	To approve Material Related Party Transaction with Tumkur Tarde Center Private Limited, being related party of Pharmaids Pharmaceuticals Limited.
12	To approve Material Related Party Transaction limits between Adita Bio Sys Private Limited (“Adita”) and Siri Labvivo Diet Private Limited (“Siri”), both being subsidiary companies of Pharmaids Pharmaceuticals Limited
13	To approve Material Related Party Transaction limits between Adita Bio Sys Private Limited and Spring Labs, both being subsidiary companies of Pharmaids Pharmaceuticals Limited
14	Approval for Sale/Disposal of land of the Company pursuant to the provisions of Section 180(1)(a) and 188(1) of the Companies Act, 2013 and Regulation 37A(1) of the Securities and Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

*Postal Ballot Notice shall be sent to the shareholders in due course and the same shall be filed with the Stoch exchange.*

The Board Meeting commenced at 2:00 P.M and concluded at 4:25 P.M.

Kindly take the same on your record and oblige.

Thanking You

**For Pharmaids Pharmaceuticals Limited**

**Prasanna Subramanya Bhat**  
**(Company Secretary & Compliance Officer)**



**Independent Auditor's Review Report on unaudited quarterly standalone financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,  
The Board of Directors of  
**Pharmaids Pharmaceuticals Limited**


We have reviewed the accompanying statement of unaudited financial results of Pharmaids Pharmaceuticals Limited ("the Company") for the quarter and nine months ended 31<sup>st</sup> December 2024 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").


This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG & Co.  
Chartered Accountants  
(Firm's Registration No. 009655S)

  
Giridhari Lal Toshniwal  
(Partner)  
(Membership No. 205140)  
UDIN: 25205140BM OPAU 2760



Place: Hyderabad  
Date: 12<sup>th</sup> February 2025

**PHARMAIDS PHARMACEUTICALS LIMITED**

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.  
CIN: L52520KA1989PLC173979

**Statement of Unaudited Standalone Financial Results for the Quarter and Nine months ended 31st December, 2024**

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Nine months ended	Nine months ended	Year ended
	Dec 31, 2024	Sep 30, 2024	Dec 31, 2023	Dec 31, 2024	Dec 31, 2023	Mar 31, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>Income</b>						
Revenue from operations	120.79	83.40	2.08	220.84	2.08	2.78
Other income	0.38	0.51	(90.10)	1.21	-78.66	79.50
<b>Total income</b>	<b>121.17</b>	<b>83.91</b>	<b>(88.02)</b>	<b>222.04</b>	<b>-76.59</b>	<b>82.27</b>
<b>Expenses</b>						
Cost of materials consumed	0.01	-	-	0.01	-	-
Purchase of stock-in-trade	80.35	61.50	1.87	163.55	1.87	25.42
Changes in inventories of finished goods and work-in-progress	25.53	4.10	-	22.93	-	(22.93)
Employee benefits expense	86.66	71.71	85.68	232.33	199.04	198.78
Finance costs	6.99	1.27	-	9.54	-	33.34
Depreciation and amortisation expense	4.96	4.96	1.42	14.70	3.11	17.72
Other expenses	101.18	59.00	44.01	259.58	193.63	438.62
<b>Total expenses</b>	<b>305.68</b>	<b>202.54</b>	<b>132.98</b>	<b>702.64</b>	<b>397.65</b>	<b>690.95</b>
<b>Profit/ (Loss) before exceptional items and tax</b>	<b>(184.51)</b>	<b>(118.63)</b>	<b>(221.00)</b>	<b>(480.59)</b>	<b>(474.23)</b>	<b>(608.67)</b>
<b>Exceptional items</b>	-	-	-	-	-	-
Prior period share of profit/interest form Associate	-	-	-	-	3.81	-
<b>Profit/ (Loss) before tax</b>	<b>(184.51)</b>	<b>(118.63)</b>	<b>(221.00)</b>	<b>(480.59)</b>	<b>(470.42)</b>	<b>(608.67)</b>
<b>Tax expense</b>						
Current tax	-	-	-	-	-	-
Deferred tax	(25.22)	(17.97)	(57.57)	(58.31)	(126.50)	(113.69)
<b>Total Tax Expense</b>	<b>(25.22)</b>	<b>(17.97)</b>	<b>(57.57)</b>	<b>(58.31)</b>	<b>(126.50)</b>	<b>(113.69)</b>
<b>Profit/ (Loss) for the year</b>	<b>(159.29)</b>	<b>(100.66)</b>	<b>(163.44)</b>	<b>(422.28)</b>	<b>(343.91)</b>	<b>(494.98)</b>
<b>Other comprehensive income</b>						
<b>(i) Items that will not be reclassified subsequently to profit or loss</b>						
Re-measurement on defined benefit plans and equity instruments	-	-	-	-	-	-
Income tax effect	-	-	-	-	-	-
<b>(ii) Items that will be reclassified subsequently to profit or loss</b>						
Effective portion of gains/(losses) on hedging instrument in cash flow hedges	-	-	-	-	-	-
Income tax effect	-	-	-	-	-	-
<b>Other comprehensive income for the year, net of taxes</b>	-	-	-	-	-	-
<b>Total comprehensive income for the year</b>	<b>(159.29)</b>	<b>(100.66)</b>	<b>(163.44)</b>	<b>(422.28)</b>	<b>(343.91)</b>	<b>(494.98)</b>

**PHARMAIDS PHARMACEUTICALS LIMITED**

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

CIN: L52520KA1989PLC173979

**Statement of Unaudited Standalone Financial Results for the Quarter and Nine months ended 31st December, 2024**

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Nine months ended	Nine months ended	Year ended
	Dec 31, 2024	Sep 30, 2024	Dec 31, 2023	Dec 31, 2024	Dec 31, 2023	Mar 31, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>Paid-up Equity share capital (Face value Rs. 10/- per share)</b>	<b>3,526.78</b>	<b>3,526.78</b>	<b>2,144.38</b>	<b>3,526.78</b>	<b>2,144.38</b>	<b>3,526.78</b>
<b>Other Equity (excluding revaluation reserve)</b>						3,579.31
<b>Earnings per equity share</b>						
Basic (in Rs)	(0.45)	(0.29)	(0.76)	(1.20)	(1.60)	(2.18)
Diluted (in Rs)	(0.45)	(0.29)	(0.73)	(1.20)	(1.54)	(2.18)

Place: Bengaluru

Date: 12-02-2025

**By the order of the Board of Directors  
For Pharmaids Pharmaceuticals Limited****Venu Madhava Kaparthy**

Whole Time Director

DIN : 00021699

**Notes to Accounts:**

1. The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its respective meetings held on February 12, 2025.
2. The unaudited standalone financials results of the company have been prepared in accordance with the Ind AS as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act 2013 read with rule 3 of the Companies (Indian Accounting Standard) Rules 2015 (as amended) and in terms of regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The company operates in a single segment of providing Contract Research and Manufacturing Services.
4. The figures for the previous periods have been regrouped / reclassified wherever considered necessary.

Place: Bengaluru

Date: 12-02-2025

**By the order of the Board of Directors  
For Pharmaids Pharmaceuticals Limited****Venu Madhava Kaparthy**

Whole Time Director

DIN : 00021699



**Independent Auditor's Review Report on consolidated unaudited quarterly financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
The Board of Directors,  
Pharmaids Pharmaceuticals Limited (Holding Company)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Pharmaids Pharmaceuticals Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its subsidiaries for the quarter and nine months ended 31<sup>st</sup> December 2024 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
  - i. Adita Bio Sys Private Limited
  - ii. Siri Labvivo Diet Private Limited
  - iii. Anugraha Chemicals
  - iv. Spring Labs
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement,

prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of 2 subsidiaries included in the consolidated unaudited financial results, whose interim financial information / financial results reflect total revenues of Rs. 387.12 lakhs and Rs. 1,284.06 lakhs, total netprofit/(loss) after tax of Rs. (221.75) lakhs and Rs. (650.41) lakhs and total comprehensive income/(loss) of Rs. (221.74) lakhs and Rs. (650.40) lakhs for the quarter and nine months ended 31<sup>st</sup> December 2024, respectively as considered in the Statement.

These interim financial statements / financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Consolidated Financial Statement is not modified in respect of the above matters.

For PPKG & Co.  
Chartered Accountants  
(Firm's Registration No. 009655S)

  
Giridhari Lal Toshniwal  
(Partner)  
(Membership No. 205140)  
UDIN: 252051408 m OPA V 5469



Place: Hyderabad  
Date: 12<sup>th</sup> February 2025



**PHARMAIDS PHARMACEUTICALS LIMITED**

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

CIN: L52520KA1989PLC173979

**Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months ended 31st December, 2024**

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Nine months ended	Nine months ended	Year ended
	Dec 31, 2024	Sep 30, 2024	Dec 31, 2023	Dec 31, 2024	Dec 31, 2023	Mar 31, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>Income</b>						
Revenue from operations	470.93	523.93	2.08	1,467.93	2.08	1,511.21
Other income	0.73	1.32	(90.10)	3.00	(78.66)	87.82
<b>Total income</b>	<b>471.66</b>	<b>525.25</b>	<b>(88.02)</b>	<b>1,470.93</b>	<b>(76.59)</b>	<b>1,599.03</b>
<b>Expenses</b>						
Cost of materials consumed	204.46	236.22	-	716.91	-	1,053.10
Purchase of stock-in-trade	99.01	110.35	1.87	242.83	1.87	4.40
Changes in inventories of finished goods and work-in-progress	(4.28)	4.66	-	68.60	-	116.23
Employee benefits expense	324.80	287.06	85.68	911.06	199.04	919.61
Finance costs	48.46	33.46	-	108.05	-	156.83
Depreciation and amortisation expense	63.89	61.48	1.42	181.96	3.11	172.49
Other expenses	135.42	141.42	44.01	413.50	193.63	656.70
<b>Total expenses</b>	<b>871.76</b>	<b>874.65</b>	<b>132.98</b>	<b>2,642.90</b>	<b>397.65</b>	<b>3,079.36</b>
<b>Profit/ (Loss) before exceptional items and tax</b>	<b>(400.09)</b>	<b>(349.39)</b>	<b>(221.00)</b>	<b>(1,171.97)</b>	<b>(474.23)</b>	<b>(1,480.33)</b>
<b>Exceptional items</b>	(1.19)	(6.95)	-	(15.76)	-	(81.81)
Prior period share of profit/interest form Associate	-	-	-	-	3.81	-
<b>Profit/ (Loss) before tax</b>	<b>(401.28)</b>	<b>(356.34)</b>	<b>(221.00)</b>	<b>(1,187.73)</b>	<b>(470.42)</b>	<b>(1,562.14)</b>
<b>Tax expense</b>						
Current tax	-	-	-	-	-	-
Tax paid for earlier years	5.9131	0.37	-	6.29	-	-
Deferred tax	(105.75)	(100.41)	(57.57)	(323.81)	(126.50)	(377.82)
<b>Total Tax Expense</b>	<b>(99.83)</b>	<b>(100.03)</b>	<b>(57.57)</b>	<b>(317.53)</b>	<b>(126.50)</b>	<b>(377.82)</b>
<b>Profit/ (Loss) for the year</b>	<b>(301.45)</b>	<b>(256.31)</b>	<b>(163.44)</b>	<b>(870.21)</b>	<b>(343.91)</b>	<b>(1,184.31)</b>
<b>Other comprehensive income</b>						
<b>(i) Items that will not be reclassified subsequently to profit or loss</b>						
Re-measurement on defined benefit plans and equity instruments	-	-	-	-	-	(46.51)
Income tax effect	-	-	-	-	-	14.51
<b>(ii) Items that will be reclassified subsequently to profit or loss</b>						
Effective portion of gains/(losses) on hedging instrument in cash flow hedges	0.01	-	-	0.01	-	-
Income tax effect	-	-	-	-	-	-
<b>Other comprehensive income for the year, net of taxes</b>	<b>0.01</b>	<b>-</b>	<b>-</b>	<b>0.01</b>	<b>-</b>	<b>(32.00)</b>
<b>Total comprehensive income for the year</b>	<b>(301.44)</b>	<b>(256.31)</b>	<b>(163.44)</b>	<b>(870.20)</b>	<b>(343.91)</b>	<b>(1,216.31)</b>



**PHARMAIDS PHARMACEUTICALS LIMITED**

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

CIN: L52520KA1989PLC173979

**Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months ended 31st December, 2024**

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Nine months ended	Nine months ended	Year ended
	Dec 31, 2024	Sep 30, 2024	Dec 31, 2023	Dec 31, 2024	Dec 31, 2023	Mar 31, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>Profit/ (Loss) attributable to:</b>						
Equity holders of the Holding company	(193.34)	(222.00)	(163.44)	(683.78)	(343.91)	(796.80)
Non-controlling interest	(108.10)	(34.30)	-	(186.43)	-	(387.51)
<b>Profit/ (Loss) for the year</b>	<b>(301.45)</b>	<b>(256.31)</b>	<b>(163.44)</b>	<b>(870.21)</b>	<b>(343.91)</b>	<b>(1,184.31)</b>
<b>Other comprehensive income attributable to:</b>						
Equity holders of the Holding company	0.01	-	-	0.01	-	(11.96)
Non-controlling interest	0.00	-	-	0.00	-	(20.04)
<b>Other comprehensive income for the year</b>	<b>0.01</b>	<b>-</b>	<b>-</b>	<b>0.01</b>	<b>-</b>	<b>(32.00)</b>
<b>Total comprehensive income attributable to:</b>						
Equity holders of the Holding company	(193.34)	(222.00)	(163.44)	(683.78)	(343.91)	(808.75)
Non-controlling interest	(108.10)	(34.30)	-	(186.43)	-	(407.55)
<b>Total comprehensive income for the year</b>	<b>(301.44)</b>	<b>(256.31)</b>	<b>(163.44)</b>	<b>(870.20)</b>	<b>(343.91)</b>	<b>(1,216.31)</b>
<b>Paid-up Equity share capital (Face value Rs. 10/- per share)</b>	<b>3,526.78</b>	<b>3,526.78</b>	<b>2,144.38</b>	<b>3,526.78</b>	<b>2,144.38</b>	<b>3,526.78</b>
<b>Other Equity (excluding revaluation reserve)</b>						<b>3,677.91</b>
<b>Earnings per equity share</b>						
Basic (in Rs)	(0.55)	(0.73)	(0.76)	(0.73)	(1.60)	(3.56)
Diluted (in Rs)	(0.55)	(0.73)	(0.73)	(0.73)	(1.54)	(3.56)

Place: Bengaluru

Date: 12-02-2025

**By the order of the Board of Directors**  
**For Pharmaids Pharmaceuticals Limited**

**Venu Madhava Kaparthy**

Whole Time Director

DIN : 00021699

**Notes to Accounts:**

1. The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its respective meetings held on February 12, 2025.
2. The unaudited consolidated financials results of the company have been prepared in accordance with the Ind AS as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act 2013 read with rule 3 of the Companies (Indian Accounting Standard) Rules 2015 (as amended) and in terms of regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The group operates in a single segment of providing Contract Research and Manufacturing Services.
4. The figures for the previous periods have been regrouped / reclassified wherever considered necessary.

Place: Bengaluru  
Date: 12-02-2025

**By the order of the Board of Directors  
For Pharmaids Pharmaceuticals Limited**

**Venu Madhava Kaparthy**  
Whole Time Director  
DIN : 00021699



**Brief particulars of the Director/KMP proposed to be appointed/ reappointed.**

S. N	Particulars	Details
1	Reasons for Change viz. Appointment /re-appointment, resignation, removal, death or otherwise	<p>Mr. Venu Madhava Kaparthy' s current term as Whole Time Director ends with effect from closing of business hours of May 20, 2025.</p> <p>Based on the recommendations of Nomination and Remuneration and subject to the approval of the Shareholders, the Board in its meeting held on February 12, 2025, re-appointed Mr. Venu Madhava Kaparthy (DIN: 00021699) as a Whole-time Director designated as Executive Director for a further period of 3 years with effect from May 21, 2025, including the payment of remuneration thereof.</p>
2	Date of appointment/re-appointment & Term of appointment/re-appointment	<p>May 21, 2025 (Subject to approval of shareholders)</p> <p>Terms of Appointment: As recommended by the Nomination and Remuneration Committee and agreed by the Board of Directors.</p>
3	Brief profile	<p>Mr. Venu Madhava Kaparthy, is a Qualified Chartered Accountant and Cost Accountant, having experience with more than 2+ decades in dealing with Banking and Finance Industry. He has vast experience in the field of Audit, Assurance, Tax, ERP, Corporate Treasury, Investment Banking. He has held senior positions in large organisations like ITC Limited, Britannia Industries Limited, Praxair India Private Limited, Makven Capital Private Limited, Bionees India Private Limited. In his past role as CFO of Bionees India Pvt. Ltd., he was instrumental in working closely with the Board and enhancing the overall business and Shareholder value significantly.</p>
4	Disclosure of Relationships between Directors	<p>There are no inter-se relations between Mr. Venu Madhava Kaparthy and the other members of the Board or the Senior Management and Key Managerial Personnel of the Company.</p>

**For Pharmaids Pharmaceuticals Limited**

**Prasanna Subramanya Bhat**  
**(Company Secretary & Compliance Officer)**



### Brief particulars of the Director/KMP proposed to be ~~appointed~~/ reappointed.

S. N	Particulars	Details
1	Reasons for Change viz. <del>Appointment</del> /re-appointment, resignation, removal, death or otherwise	<p>Ms. Mini Manikantan's current term as Whole Time Director ends with effect from closing of business hours of July 08, 2025.</p> <p>Based on the recommendations of Nomination and Remuneration and subject to the approval of the Shareholders, the Board in its meeting held on February 12, 2025, re-appointed Ms. Mini Manikantan (DIN: 09663184) as a Whole-time Director designated as Executive Director for a further period of 3 years with effect from July 09, 2025, including the payment of remuneration thereof.</p>
2	Date of appointment/re-appointment & Term of appointment/re-appointment	<p>July 09, 2025 (Subject to approval of shareholders)</p> <p>Terms of Appointment: As recommended by the Nomination and Remuneration Committee and agreed by the Board of Directors.</p>
3	Brief profile	<p>Ms. Mini Manikantan, with over 16+ years of experience in the Pharmaceutical Industry has led the Project Management since the start of career and has been instrumental in building the communication channel across the regions and is responsible for the Company's end-to-end operational service. She spearheaded innovative partnerships via execution, CRO identification, Site Evaluation, Strategy Preparation, Financial Evaluations, Time Management, Budgeting, Commercials and Operations. She's previously worked with companies like Dr. Reddy's Lab and Eurofins Advinus.</p>
4	Disclosure of Relationships between Directors	<p>There are no inter-se relations between Ms. Mini Manikantan and the other members of the Board or the Senior Management and Key Managerial Personnel of the Company.</p>

**For Pharmaids Pharmaceuticals Limited**

**Prasanna Subramanya Bhat**  
**(Company Secretary & Compliance Officer)**



## **Brief summary of Amendments to Memorandum of Association of the Company**

### **Changes/Modification/Alteration (Subject to the approval of shareholders)**

#### **Increase in Authorised Share Capital**

The Existing Authorised Share Capital under Clause V will be increased from Rs. 45,00,00,000/- (Rupees Forty-Five Crore Only) divided into 4,50,00,000 (Four Crore Fifty Lakh) Equity Shares of Rs. 10/- (Rupees Ten Only) to Rs. 1,01,00,00,000/- (Rupees One Hundred and One Crore Only) consisting of 10,10,00,000 (Ten Crore Ten Lakh) equity shares of Rs. 10/- (Rupees Ten Only) each and Consequential Alteration in the Capital Clause of the Memorandum of Association.

**For Pharmaids Pharmaceuticals Limited**

**Prasanna Subramanya Bhat**  
**(Company Secretary & Compliance Officer)**



**Details required under the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

S. N	Particulars	Details
a	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	Not Applicable
b	Date on which the agreement for sale has been entered into	<p>The Company have approved the said transaction today i.e. 12th February 2025, subject to approval of shareholders and requisite regulatory approvals.</p> <p>As on the date of intimation, the company has not entered into any agreements with the buyer. If entered and executed any, will be duly communicated to the stock exchange within the stipulated timeframe, in compliance with the disclosure requirements under Regulation 30 of the SEBI (LODR) Regulations, 2015.</p>
c	The expected date of completion of sale/disposal	On or before April 15, 2025, unless mutually extended by the Parties.
d	Consideration received from such sale/disposal	<p>Total cash consideration of Rs. 16,50,00,000/- (Rupees Sixteen Crore Fifty Lakh Only)</p> <p>As on the date of this intimation the company has not received any consideration from the Buyer.</p>
e	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof	<p>Dr. S. N. Vinaya Babu, Chairman and Non-Executive &amp; Non Independent Director of the Company (“the Buyer”), Related party of the Company.</p> <p>Currently the buyer does not belong to the promoter/promoter group/group companies.</p> <p>The Buyer has given the open offer to the public shareholders of the company, Pursuant to the completion of open offer, the buyer will be classified as the Promoter of the Company.</p>





# Pharmaids Pharmaceuticals Limited

f	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	<p>Yes. Dr. S. N. Vinaya Babu is a related party of the Company and the transaction falls within ambit of related party transaction.</p> <p>The consideration for the transaction has been at arm’s length.</p>
g	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement	<p>Yes. The sale of land is not part of a Scheme of Arrangement.</p> <p>Further, the sale of the said land parcels attract the terms of regulation 37A of the LODR Regulations, as it constitute an undertaking or substantially the whole of the undertaking for the Company under section 180 (1)(a) of the Companies Act, 2013.</p> <p>The Board of Directors has approved to obtain shareholders’ approval by means of passing special resolution under Section 180(1)(a) and 188 of the Companies Act, 2013 through postal ballot notice.</p>
h	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable

**For Pharmaids Pharmaceuticals Limited**

**Prasanna Subramanya Bhat**  
**(Company Secretary & Compliance Officer)**



**Details required under the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

Sl. No	Particulars	Details
1	Name of party for which such guarantees or indemnity or surety was given.	Adita Bio Sys Private Limited “Adita”, material subsidiary of the Company.
2	Whether the promoter/ promoter group/ group companies have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”.	The promoter/ promoter group/ group companies do not have any interest in this transaction.
3	Brief details of such guarantee or indemnity or becoming a surety viz. brief details of agreement entered (if any) including significant terms and conditions, including amount of guarantee.	<p>The company has agreed to provide a Corporate Guarantee to any Banks/Financial Institutions for the term loan/working capital facilities for an amount of up to Rs. 25,00,00,000/- (Rupees Twenty Five Crore Only), proposed to be availed by Adita, Material subsidiary of the Company.</p> <p>As on the date of intimation, the company has not entered into any agreements. If entered and executed any, will be duly communicated to the stock exchange within the stipulated timeframe, in compliance with the disclosure requirements under Regulation 30 of the SEBI (LODR) Regulations, 2015.</p>
4	Impact of such guarantees or indemnity or surety on listed entity.	<p>The corporate guarantee provided is a contingent liability for the Company.</p> <p>This guarantee has been provided on behalf of a subsidiary of the Company which is part of the consolidated group. At this point, there is no impact of this guarantee on the Company.</p>

**For Pharmaids Pharmaceuticals Limited**

**Prasanna Subramanya Bhat**  
**(Company Secretary & Compliance Officer)**